Alphagan patent ruling
Executive Summary
Allergan's lawsuit for induced infringement against Alcon and Bausch & Lomb was properly dismissed because the two companies' ANDAs for brimonidine did not seek FDA approval for uses claimed in two Allergan patents, U.S. appeals court rules March 28 (1"The Pink Sheet" Jan. 27, p. 18)...
You may also be interested in...
Neurontin Bulk Supply May Limit Generic Uptake, Pfizer Says
Neurontin generics will have to overcome limitations in the bulk drug supply in addition to Pfizer's patent defenses, Pfizer CEO Henry McKinnell told a Jan. 22 earnings conference call
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.